PMID: 9445059Jan 28, 1998Paper

Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines

Journal of Virology
R I ConnorS M Wolinsky

Abstract

We have studied 18 participants in phase I/II clinical trials of recombinant gp120 (rgp120) subunit vaccines (MN and SF-2) who became infected with human immunodeficiency virus type 1 (HIV-1) during the course of the trials. Of the 18 individuals, 2 had received a placebo vaccine, 9 had been immunized with MN rgp120, and seven had been immunized with SF-2 rgp120. Thirteen of the 18 infected vaccinees had received three or four immunizations prior to becoming infected. Of these, two were placebo recipients, six had received MN rgp120, and five had received SF-2 rgp120. Only 1 of the 11 rgp120 recipients who had multiple immunizations failed to develop a strong immunoglobulin G antibody response to the immunogen. However, the antibody response to rgp120 was transient, typically having a half-life of 40 to 60 days. No significant neutralizing activity against the infecting strain was detected in any of the infected individuals at any time prior to infection. Antibody titers in subjects infected despite vaccination and in noninfected subjects were not significantly different. Envelope-specific cytotoxic T-lymphocyte responses measured after infection were infrequent and weak in the nine vaccinees who were tested. HIV-1 was isolated...Continue Reading

References

Jul 1, 1977·Journal of Dental Research·M E SchaefferJ R McGhee
Aug 1, 1992·AIDS Research and Human Retroviruses·B KorberG Myers
Mar 1, 1992·The Journal of Infectious Diseases·M T RoosM Tersmette
Sep 1, 1992·AIDS Research and Human Retroviruses·B Korber, G Myers
Aug 1, 1992·AIDS Research and Human Retroviruses·G Myers, R Lenroot
Oct 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·D D HoN C Sun
Jan 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·M GirardE Muchmore
Oct 5, 1990·Journal of Molecular Biology·S F AltschulD J Lipman
Jan 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·R F Smith, T F Smith
Sep 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·E S DaarD D Ho
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·P W BermanL A Lasky
Feb 9, 1989·Nature·D J CaponJ E Groopman
Jul 15, 1989·BMJ : British Medical Journal·C PedersenT Karlsmark
May 18, 1989·Nature·S Kwok, R Higuchi
Jan 1, 1988·Annual Review of Genetics·J Felsenstein
Aug 1, 1988·Trends in Biochemical Sciences·D V Faulkner, J Jurka
Jan 1, 1985·Methods in Enzymology·J Mestecky, M Kilian
Mar 12, 1982·Journal of Immunological Methods· Fazekas de St Groth
Jan 1, 1981·Journal of Molecular Evolution·J Felsenstein
Nov 16, 1995·Nature·B T KorberS Wolinsky
Jan 1, 1995·Journal of Computational Biology : a Journal of Computational Molecular Cell Biology·S R EddyR Durbin
Dec 1, 1995·The Journal of Experimental Medicine·S I StapransM B Feinberg
Apr 12, 1994·Proceedings of the National Academy of Sciences of the United States of America·A J ConleyE A Emini

❮ Previous
Next ❯

Citations

May 19, 1998·Nature Medicine·D R Burton, J P Moore
Jan 17, 2002·Immunopharmacology and Immunotoxicology·Y LuY H Chen
Aug 15, 2002·British Medical Bulletin·Andrew McMichaelTomas Hanke
Jun 25, 2005·Journal of Medical Virology·Sibusiso P NkosiMaria A Papathanasopoulos
Jun 19, 2010·The Journal of Biological Chemistry·Sanchari BhattacharyyaRaghavan Varadarajan
Oct 19, 2011·The Journal of Clinical Investigation·Alexandra M OrtizGuido Silvestri
May 10, 2016·European Journal of Gastroenterology & Hepatology·El-Shatat A TosonAml M El-Sharkawy
Jun 17, 1999·Nature Medicine·A J McMichael, T Hanke
May 18, 2005·The Biochemical Journal·Kausik ChakrabortyRaghavan Varadarajan
Nov 21, 2001·British Medical Bulletin·B KorberV Detours
May 11, 2002·Nature Reviews. Immunology·Andrew McMichael, Tomâs Hanke
Dec 14, 2004·AIDS Research and Human Retroviruses·Kelly R YoungTed M Ross
Aug 3, 2004·Expert Review of Vaccines·James I MullinsGerald H Learn
Sep 17, 2004·International Reviews of Immunology·Veljko VeljkovicTatjana Veljkovic
May 15, 2009·Journal of Virology·Bette T KorberBarton F Haynes
Feb 13, 2013·The Journal of Experimental Medicine·Laura E McCoy, Robin A Weiss
Apr 19, 2011·AIDS Research and Human Retroviruses·Per Johan KlasseJohn P Moore
Jan 17, 2014·American Journal of Reproductive Immunology : AJRI·Ruizhong Shen, Phillip D Smith

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.